The organization that took a Stanford University rare-disease spinout public 14 months ago now says it wants to buy the remainder of the company.
BridgeBio Pharma Inc., whose own $348 million initial public offering in June is the largest biotech IPO this year, disclosed in a letter filed Friday with the Securities and Exchange Commission that it wants to buy the one-third of Eidos Therapeutics Inc. that it doesn't already own. The nonbinding "expression of interest" in the San Francisco company…
